EU Revokes Hisun Pharmaceutical's Non-Compliance Status for Cancer Drug Facility

MT Newswires Live10-20

The European Medicines Agency revoked Zhejiang Hisun Pharmaceutical's (SHA:600267) non-compliance declaration for the phase 2 anti-cancer facility in Taizhou, China, according to a Monday filing with the Shanghai bourse.

The facility, which produces anti-cancer drugs, received a non-compliance status for its facilities due to cross-contamination and non-adherence to quality system controls, among others, the filing said.

In February 2022, the EU partially revoked the plant's non-compliance status, but its cytotoxic and hazardous active pharmaceutical ingredients remained non-compliant, the filing said.

Shares closed 2% higher on Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2576834591?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 17:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576834591","market":"us","top_or_hot":-1,"title":"EU Revokes Hisun Pharmaceutical's Non-Compliance Status for Cancer Drug Facility","media":"MT Newswires Live","content":"<html><body><p> The European Medicines Agency revoked <a href=\"https://laohu8.com/S/600267\">Zhejiang Hisun</a> Pharmaceutical's (SHA:600267) non-compliance declaration for the phase 2 anti-cancer facility in Taizhou, China, according to a Monday filing with the Shanghai bourse.</p><p>The facility, which produces anti-cancer drugs, received a non-compliance status for its facilities due to cross-contamination and non-adherence to quality system controls, among others, the filing said.</p><p>In February 2022, the EU partially revoked the plant's non-compliance status, but its cytotoxic and hazardous active pharmaceutical ingredients remained non-compliant, the filing said.</p><p>Shares closed 2% higher on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EU Revokes Hisun Pharmaceutical's Non-Compliance Status for Cancer Drug Facility</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEU Revokes Hisun Pharmaceutical's Non-Compliance Status for Cancer Drug Facility\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-20 17:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> The European Medicines Agency revoked <a href=\"https://laohu8.com/S/600267\">Zhejiang Hisun</a> Pharmaceutical's (SHA:600267) non-compliance declaration for the phase 2 anti-cancer facility in Taizhou, China, according to a Monday filing with the Shanghai bourse.</p><p>The facility, which produces anti-cancer drugs, received a non-compliance status for its facilities due to cross-contamination and non-adherence to quality system controls, among others, the filing said.</p><p>In February 2022, the EU partially revoked the plant's non-compliance status, but its cytotoxic and hazardous active pharmaceutical ingredients remained non-compliant, the filing said.</p><p>Shares closed 2% higher on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0060","symbol_name":"抗癌","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2576834591","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576834591","pubTimestamp":1760950842,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"The European Medicines Agency revoked Zhejiang Hisun Pharmaceutical's  non-compliance declaration for the phase 2 anti-cancer facility in Taizhou, China, according to a Monday filing with the Shanghai bourse.The facility, which produces anti-cancer drugs, received a non-compliance status for its facilities due to cross-contamination and non-adherence to quality system controls, among others, the filing said.In February 2022, the EU partially revoked the plant's non-compliance status, but its cytotoxic and hazardous active pharmaceutical ingredients remained non-compliant, the filing said.Shares closed 2% higher on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600267":"海正药业","BK0060":"抗癌","BK0028":"国家队","BK0239":"医药制造","BK4156":"煤与消费用燃料","BK0188":"融资融券"},"translate_title":"欧盟撤销海正药业抗癌药物设施不合规地位","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600267":0.9},"content_text":"The European Medicines Agency revoked Zhejiang Hisun Pharmaceutical's (SHA:600267) non-compliance declaration for the phase 2 anti-cancer facility in Taizhou, China, according to a Monday filing with the Shanghai bourse.The facility, which produces anti-cancer drugs, received a non-compliance status for its facilities due to cross-contamination and non-adherence to quality system controls, among others, the filing said.In February 2022, the EU partially revoked the plant's non-compliance status, but its cytotoxic and hazardous active pharmaceutical ingredients remained non-compliant, the filing said.Shares closed 2% higher on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2576834591","isCrawlerRequest":true}